This Week in Cell

University of California, Los Angeles, and Vanderbilt-Ingram Cancer Center researchers track the genomic and transcriptomic effects of immunotherapy-based treatment for metastatic melanoma in Cell. The team did whole-exome sequencing and/or RNA-sequencing on 38 metastatic melanoma tumors, before and after treatment with pembrolizumab or nivolumab — therapies designed to interfere with the PD-1 immune checkpoint blockade.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.